Canadian Halal Investor.

NASDAQ Shariah screener · October 2026

Is Vertex Pharmaceuticals Incorporated (VRTX) Halal?

PASS

Vertex Pharmaceuticals Incorporated · NASDAQ: VRTX · Healthcare

The short answer

Yes — Vertex Pharmaceuticals (VRTX) passes this Shariah stock screen. The Boston, Massachusetts company discovers and sells therapies for serious diseases: cystic fibrosis medicines led by TRIKAFTA/KAFTRIO ($10,312.7M of FY2025 revenue, about 85.9%) plus the newer ALYFTREK, the CRISPR gene-edited therapy CASGEVY, and the non-opioid pain medicine JOURNAVX — all pharmaceutical activity, with no haram business segments disclosed in its FY2025 filings. The financial ratios pass comfortably: the Q2 2026 balance sheet carries no interest-bearing debt at all (0.00% of its ~$133.1B market cap, October 2026, Finnhub), below the ~33% ceiling, and FY2025 interest income of $490.9M is 4.09% of revenue ($12,001.3M), below the 5% ceiling. MuslimXchange rates VRTX Shariah-compliant (updated September 10, 2026); Zoya covers VRTX but its public rating text is contradictory (inconclusive). This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

Gate 1 — Business activity: PASS

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), founded in 1989 and headquartered in Boston, Massachusetts, discovers, develops and commercialises therapies for serious diseases. Marketed products: cystic fibrosis medicines — TRIKAFTA/KAFTRIO, ALYFTREK (newest CFTR modulator, approved in the U.S., U.K., EU, Canada, New Zealand, Switzerland, Australia and Israel for patients 6 years and older), KALYDECO, ORKAMBI and SYMDEKO/SYMKEVI; CASGEVY, a non-viral ex vivo CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia (64 patients infused in 2025; approved in the U.S., U.K., EU, Saudi Arabia, Bahrain, Qatar, Canada, Switzerland, UAE and Kuwait for 12 years and older); and JOURNAVX (suzetrigine), a first-in-class oral non-opioid NaV 1.8 pain-signal inhibitor for moderate-to-severe acute pain (over 550,000 prescriptions written and filled through year-end 2025). The pipeline includes povetacicept for IgA nephropathy (rolling BLA filing for U.S. accelerated approval in the first half of 2026; FDA Breakthrough Therapy designation), inaxaplin for APOL1-mediated kidney disease, and zimislecel for Type 1 diabetes. FY2025 total revenue of $12,001.3M = product revenues $11,970.6M (TRIKAFTA/KAFTRIO $10,312.7M + ALYFTREK $837.8M + other product revenues $820.1M, including CASGEVY $115.8M and JOURNAVX $59.6M) + other revenues $30.7M. Business-screen implication (factual): all activity is pharmaceuticals/healthcare; the filings disclose no alcohol, gambling, conventional finance, pork, weapons or tobacco revenue — no haram segments. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per Vertex's Q2 2026 results (announced August 3, 2026; SEC CIK 0000875320), the condensed consolidated balance sheet as of June 30, 2026 lists no debt lines at all — no short-term debt, no long-term debt, no borrowings (liabilities are accounts payable and accrued expenses $3,608.5M, other current liabilities $329.4M, long-term operating lease liabilities $1,977.6M and other long-term liabilities $1,259.9M). Total interest-bearing debt is effectively $0. Against a market cap of about $133.1B (Finnhub, October 2026), debt ÷ market cap is 0.00% — below the ~33% ceiling. Cash, cash equivalents and marketable securities of $13,641.5M (current $7,852.4M + long-term $5,789.1M) are about 10.25% of market cap, also below 33%. The debt gate passes. Facts only.

Gate 3 — Non-compliant income: PASS

Vertex's 8-K filed February 12, 2026 reporting the year ended December 31, 2025 (SEC CIK 0000875320) reports 'Interest income' of $490.9M against FY2025 total revenues of $12,001.3M — about 4.09% of revenue, below the 5% non-compliant income ceiling. Interest expense was only $13.3M for the year. This is the broadest verifiable interest income line from primary filings, and Zoya's own VRTX page cites this same $490.9M figure and computes 4.07% against its $12,074.6M revenue total. The income gate passes. Facts only.

Key figures used

Frequently asked questions

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals Incorporated, founded in 1989 and headquartered in Boston, Massachusetts, discovers, develops and commercialises therapies for serious diseases. Its marketed products are the cystic fibrosis (CF) medicines TRIKAFTA/KAFTRIO, ALYFTREK (the newest CFTR modulator, approved in the U.S., U.K., EU, Canada, New Zealand, Switzerland, Australia and Israel for patients 6 years and older), KALYDECO, ORKAMBI and SYMDEKO/SYMKEVI; CASGEVY, a CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia; and JOURNAVX (suzetrigine), a first-in-class non-opioid NaV 1.8 pain-signal inhibitor approved in the U.S. for moderate-to-severe acute pain. The pipeline includes povetacicept for IgA nephropathy (rolling BLA filing for U.S. accelerated approval in the first half of 2026), inaxaplin for APOL1-mediated kidney disease, and zimislecel for Type 1 diabetes. FY2025 total revenue was $12,001.3M — product revenues of $11,970.6M (TRIKAFTA/KAFTRIO $10,312.7M, ALYFTREK $837.8M, other product revenues $820.1M including CASGEVY $115.8M and JOURNAVX $59.6M) plus other revenues of $30.7M — all pharmaceutical activity with no haram segments disclosed.

Why does VRTX pass this Shariah stock screen?

VRTX passes this Shariah stock screen at all three gates. Gate 1 (business activities): prescription pharmaceuticals, gene-edited cell therapy and non-opioid pain medicine are healthcare activity — the FY2025 filings disclose no alcohol, gambling, conventional finance, pork, weapons or tobacco revenue. Gate 2 (debt): the Q2 2026 condensed consolidated balance sheet carries no short-term or long-term interest-bearing debt at all, so debt ÷ market cap is 0.00% against the ~33% ceiling. Gate 3 (interest income): FY2025 interest income of $490.9M is 4.09% of $12,001.3M revenue, under the 5% ceiling. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

What is VRTX's interest-bearing debt ratio?

Per Vertex's Q2 2026 results (announced August 3, 2026; SEC CIK 0000875320), the condensed consolidated balance sheet as of June 30, 2026 lists no debt lines — no short-term debt, no long-term debt, no borrowings (liabilities are accounts payable and accrued expenses $3,608.5M, other current liabilities $329.4M, long-term operating lease liabilities $1,977.6M and other long-term liabilities $1,259.9M). Total interest-bearing debt is effectively $0. Against a market cap of about $133.1B (Finnhub, October 2026), debt ÷ market cap is 0.00% — below the ~33% ceiling. Cash, cash equivalents and marketable securities of $13,641.5M at June 30, 2026 ($7,852.4M current plus $5,789.1M long-term) are about 10.25% of market cap, also below 33%. The debt gate passes.

What is VRTX's non-compliant income ratio?

Vertex's 8-K filed February 12, 2026 reporting the year ended December 31, 2025 (SEC CIK 0000875320) reports 'Interest income' of $490.9M against FY2025 total revenues of $12,001.3M — about 4.09% of revenue, below the 5% non-compliant income ceiling. Interest expense was only $13.3M for the year. This is the broadest verifiable interest income line from primary filings, and Zoya's own VRTX page cites the same $490.9M figure (computing 4.07% against its $12,074.6M revenue total). The income gate passes.

Do Zoya, Musaffa, or ShariaPortfolio cover VRTX?

Zoya covers VRTX (zoya.finance/stocks/vrtx; updated September 2026) and cites the same $490.9M FY2025 interest income (4.07%), but its public page renders contradictory auto-generated template text (simultaneously calling VRTX Shariah-compliant/halal and not), so no clean Zoya rating is retrievable — reported as inconclusive. Musaffa: no VRTX page was found via public search — no coverage found. ShariaPortfolio: no VRTX entry found. All honestly reported as found, not invented. Separately, MuslimXchange's VRTX page (updated September 10, 2026) rates Vertex Shariah-compliant across AAOIFI and seven other standards. This page applies the screen directly from Vertex's own filings.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).